• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在甲氨蝶呤和氟尿嘧啶存在的情况下静脉注射和口服环磷酰胺的药代动力学

Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil.

作者信息

De Bruijn E A, Slee P H, Van Oosterom A T, Lameijer D W, Roozendaal K J, Tjaden U R

机构信息

Laboratory of Cancer Research & Clinical Oncology, University of Antwerp, Belgium.

出版信息

Pharm Weekbl Sci. 1988 Oct 14;10(5):200-6. doi: 10.1007/BF01956871.

DOI:10.1007/BF01956871
PMID:3205676
Abstract

Cyclophosphamide was administered to 12 breast cancer patients in combination with methotrexate and fluorouracil. Doses prescribed were cyclophosphamide 75 mg/m2, methotrexate 30 mg/m2 and fluorouracil 500 mg/m2 (per square meter body surface). Cyclophosphamide was administered intravenously and orally in aqueous solutions and in tablets in a randomized cross-over trial. Methotrexate and fluorouracil were administered intravenously, methotrexate was given first and then fluorouracil. Assays of cyclophosphamide in blood plasma were performed by capillary gas chromatography. Data of mean bioavailability of cyclophosphamide administered by tablets were suggestive of sufficient absorption. In 2 patients, however, a lower bioavailability of cyclophosphamide was demonstrated. Intra-individual differences in the terminal slope of the plasma decay curves after intravenous and oral administration in some patients decreased the calculated bioavailability of cyclophosphamide, if these values were included in the calculation of cyclophosphamide bioavailability. Compared with the administration of the solutions peak times, lag-times and mean absorption times of cyclophosphamide given in tablets were markedly prolonged. It is concluded that interactions between cyclophosphamide and methotrexate and/or fluorouracil after oral dosing as tablets are different from interactions observed after intravenous administration of cyclosphosphamide.

摘要

环磷酰胺与甲氨蝶呤和氟尿嘧啶联合应用于12例乳腺癌患者。规定剂量为环磷酰胺75mg/m²、甲氨蝶呤30mg/m²和氟尿嘧啶500mg/m²(每平方米体表面积)。在一项随机交叉试验中,环磷酰胺以水溶液和片剂形式静脉内和口服给药。甲氨蝶呤和氟尿嘧啶静脉内给药,先给予甲氨蝶呤,然后给予氟尿嘧啶。采用毛细管气相色谱法测定血浆中环磷酰胺的含量。片剂给药的环磷酰胺平均生物利用度数据表明吸收充分。然而,有2例患者环磷酰胺的生物利用度较低。如果将某些患者静脉内和口服给药后血浆衰减曲线的终末斜率的个体内差异纳入环磷酰胺生物利用度的计算中,则会降低环磷酰胺的计算生物利用度。与溶液给药相比,片剂给药的环磷酰胺的达峰时间、滞后时间和平均吸收时间明显延长。得出的结论是,口服片剂形式的环磷酰胺与甲氨蝶呤和/或氟尿嘧啶之间的相互作用与静脉内给予环磷酰胺后观察到的相互作用不同。

相似文献

1
Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil.在甲氨蝶呤和氟尿嘧啶存在的情况下静脉注射和口服环磷酰胺的药代动力学
Pharm Weekbl Sci. 1988 Oct 14;10(5):200-6. doi: 10.1007/BF01956871.
2
Bioavailability of cyclophosphamide in the CMF regimen.CMF方案中环磷酰胺的生物利用度。
Onkologie. 1990 Jun;13(3):203-6. doi: 10.1159/000216759.
3
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.环磷酰胺、表柔比星和氟尿嘧啶强化化疗与环磷酰胺、甲氨蝶呤和氟尿嘧啶治疗绝经前淋巴结阳性乳腺癌的随机试验。加拿大国家癌症研究所临床试验组
J Clin Oncol. 1998 Aug;16(8):2651-8. doi: 10.1200/JCO.1998.16.8.2651.
4
Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.环磷酰胺、甲氨蝶呤和5-氟尿嘧啶联合或不联合雌激素募集治疗转移性乳腺癌女性的随机试验
Cancer. 1994 May 1;73(9):2337-43. doi: 10.1002/1097-0142(19940501)73:9<2337::aid-cncr2820730916>3.0.co;2-q.
5
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.比较环磷酰胺、表柔比星和氟尿嘧啶与环磷酰胺、甲氨蝶呤和氟尿嘧啶用于绝经前淋巴结阳性乳腺癌女性的随机试验:加拿大国家癌症研究所临床试验组MA5试验的更新
J Clin Oncol. 2005 Aug 1;23(22):5166-70. doi: 10.1200/JCO.2005.09.423.
6
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborative Cancer Group (ICCG).环磷酰胺、甲氨蝶呤和氟尿嘧啶与氟尿嘧啶、表柔比星和环磷酰胺用于可手术的绝经前淋巴结阳性乳腺癌女性患者的随机对照研究的设计与原理。国际癌症协作组(ICCG)的一项试验
Drugs. 1993;45 Suppl 2:46-50; discussion 49-50. doi: 10.2165/00003495-199300452-00008.
7
Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.可手术乳腺癌的辅助化疗:环磷酰胺、甲氨蝶呤和氟尿嘧啶与苯丁酸氮芥、甲氨蝶呤和氟尿嘧啶的对比——瑞士临床癌症研究组SAKK 27/82试验的11年结果
J Clin Oncol. 1997 Jul;15(7):2502-9. doi: 10.1200/JCO.1997.15.7.2502.
8
Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma.环磷酰胺、甲氨蝶呤以及由亚叶酸调节的慢性口服替加氟在晚期乳腺癌患者治疗中的应用。
Cancer. 1998 Mar 1;82(5):878-85.
9
[Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].[环磷酰胺、甲氨蝶呤和5-氟尿嘧啶方案联合或不联合粒细胞集落刺激因子静脉给药在手术治疗乳腺癌中的可行性]
Minerva Med. 1993 Sep;84(9):467-72.
10
Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.在有1至3个腋窝淋巴结阳性的乳腺癌患者中,比较甲氨蝶呤和氟尿嘧啶联合或不联合环磷酰胺的辅助化疗效果。
J Natl Cancer Inst. 1993 May 19;85(10):812-7. doi: 10.1093/jnci/85.10.812.

引用本文的文献

1
Pharmacokinetic modeling of therapies for systemic lupus erythematosus.系统性红斑狼疮治疗的药代动力学建模
Expert Rev Clin Pharmacol. 2015;8(5):587-603. doi: 10.1586/17512433.2015.1059751. Epub 2015 Jul 9.
2
Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.接受造血干细胞移植患者的环磷酰胺的遗传效应的群体药代动力学分析。
Eur J Clin Pharmacol. 2013 Aug;69(8):1543-51. doi: 10.1007/s00228-013-1507-7. Epub 2013 Apr 16.
3
Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

本文引用的文献

1
Dose-response effect of adjuvant chemotherapy in breast cancer.辅助化疗在乳腺癌中的剂量反应效应。
N Engl J Med. 1981 Jan 1;304(1):10-5. doi: 10.1056/NEJM198101013040103.
2
Pharmacology of cyclophosphamide and metabolites.
Cancer Treat Rep. 1981;65 Suppl 3:89-95.
3
Some aspects of the gas--liquid chromatographic analysis of cyclophosphamide in plasma.
J Chromatogr. 1980 Jul 11;183(1):49-56. doi: 10.1016/s0378-4347(00)81397-3.
4
伊马替尼对依托泊苷和/或异环磷酰胺的药代动力学及体内疗效的影响。
BMC Pharmacol. 2007 Oct 27;7:13. doi: 10.1186/1471-2210-7-13.
4
Metabolism and pharmacokinetics of oxazaphosphorines.恶唑磷类化合物的代谢与药代动力学
Clin Pharmacokinet. 2000 Apr;38(4):291-304. doi: 10.2165/00003088-200038040-00001.
5
Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients.癌症患者口服5'-脱氧-5-氟尿苷的药代动力学和生物利用度
Br J Clin Pharmacol. 1999 Apr;47(4):351-6. doi: 10.1046/j.1365-2125.1999.00899.x.
Bioavailability of cyclophosphamide from oral formulations.
口服制剂中环磷酰胺的生物利用度。
Eur J Clin Pharmacol. 1984;26(2):269-70. doi: 10.1007/BF00630298.
5
Pharmacokinetics of the cytostatic drugs used in the CMF-regimen.CMF方案中使用的细胞毒性药物的药代动力学。
Anticancer Res. 1983 Jul-Aug;3(4):269-71.
6
Determination of the underivatized antineoplastic drugs cyclophosphamide and 5-fluorouracil and some of their metabolites by capillary gas chromatography combined with electron-capture and nitrogen-phosphorus selective detection.
J Chromatogr. 1983 Nov 25;279:603-8. doi: 10.1016/s0021-9673(01)93663-5.
7
A gas chromatographic assay for the determination of 5,6-dihydrofluorouracil and 5-fluorouracil in human plasma.一种用于测定人血浆中5,6-二氢氟尿嘧啶和5-氟尿嘧啶的气相色谱分析法。
J Chromatogr. 1983 Dec 9;278(2):283-9. doi: 10.1016/s0378-4347(00)84787-8.
8
Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration.健康受试者静脉注射和口服布罗替唑仑后的药代动力学
Br J Clin Pharmacol. 1983;16 Suppl 2(Suppl 2):285S-290S. doi: 10.1111/j.1365-2125.1983.tb02302.x.
9
Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations.
Arzneimittelforschung. 1984;34(3):313-6.
10
[Bioavailability of cyclophosphamide following oral administration in high doses].[大剂量口服环磷酰胺后的生物利用度]
Onkologie. 1984 Feb;7(1):48-9. doi: 10.1159/000215401.